Cryoneurolysis for Painful Diabetic Neuropathy of the Foot
NCT: NCT06646731 · ACTIVE_NOT_RECRUITING
Brief Summary
The study is a single-center, randomized, participant- and observer-masked, human-subjects, post-market clinical pilot study to investigate the use of ultrasound-guided percutaneous cryoneurolysis to treat diabetic neuropathy of the foot. A prolonged nerve block may be provided by freezing the nerve using a technique called "cryoneurolysis". With cryoneurolysis and ultrasound machines, a small needle-like "probe" may be placed through anesthetized skin and guided to the target nerve to allow freezing. The procedure takes about 6 minutes for each nerve, involves little discomfort, has no systemic side effects, and cannot be misused or become addictive. Participants will be randomly allocated to one of two possible treatments groups: cryoneurolysis (experimental) or sham (control). The primary outcome measure is the change in pain on the neuropathic pain scale from baseline 1 month following the procedure.
Frequently Asked Questions
What is Cryoneurolysis for Painful Diabetic Neuropathy of the Foot?
Cryoneurolysis for Painful Diabetic Neuropathy of the Foot is a clinical trial registered under NCT06646731. Current status: ACTIVE_NOT_RECRUITING.
What is the status of NCT06646731?
The current status of NCT06646731 (Cryoneurolysis for Painful Diabetic Neuropathy of the Foot) is: ACTIVE_NOT_RECRUITING.
When did Cryoneurolysis for Painful Diabetic Neuropathy of the Foot start?
Cryoneurolysis for Painful Diabetic Neuropathy of the Foot started on 2025-08-25.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.